NCT00032188View on ClinicalTrials.gov

Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

January 31, 2002

Primary Completion Date

June 30, 2006

Conditions
Recurrent Renal Cell CancerStage III Renal Cell CancerStage IV Renal Cell Cancer
Interventions
BIOLOGICAL

aldesleukin

Given subcutaneously

DRUG

bryostatin 1

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

60637-1470

University of Chicago Comprehensive Cancer Center, Chicago

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00032188 - Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer | Biotech Hunter | Biotech Hunter